Sexually Transmitted Diseases, Bacterial
14
1
2
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.1%
1 terminated out of 14 trials
90.9%
+4.4% vs benchmark
14%
2 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 10 completed trials
Clinical Trials (14)
Game Plan: Efficacy of a Brief, Web-based Intervention on Alcohol Use and Sexually-transmitted Infections
Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM
Mobile Enhanced Prevention Support for People Leaving Jail
Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP
Alignment of PrEP Use With HIV Risk in Young Women and Men
The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Same-Day PrEP Initiation and Sexual Health for Transgender Women
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
Mycoplasma Species and the Genitourinary System
Psychoeduc Interv. Through Meta-universes on Condom's Use Self - Efficacy and Sexual Behavior in Students of UAChile
Evaluation of Presumptive Periodic Treatment (PPT) of Sexually Transmitted Infections (STIs)
Self-taken Penile Meatal Swabs for Chlamydia, Gonorrhoea and Mycoplasma Genitalium Detection
UROGEN WELL D-ONE : Evaluation of a Novel Diagnostic for Sexually Transmitted Bacterial Infections
Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of STIs